Need Help?

Chromatin run-on and RNA sequencing of fibrolamellar carcinoma

Fibrolamellar carcinoma (FLC) is a rare, therapeutically intractable liver cancer that disproportionately affects youth. Here we used chromatin run-on sequencing to characterize the enhancer landscape in FLC and RNA sequencing to identify dysregulated genes in FLC.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001005797 NextSeq 500 30
Publications Citations
Hotspots of Aberrant Enhancer Activity in Fibrolamellar Carcinoma Reveal Candidate Oncogenic Pathways and Therapeutic Vulnerabilities.
Cell Rep 31: 2020 107509
20
DNAJB1-PRKACA in HEK293T cells induces LINC00473 overexpression that depends on PKA signaling.
PLoS One 17: 2022 e0263829
5
Multiomic analysis of microRNA-mediated regulation reveals a proliferative axis involving miR-10b in fibrolamellar carcinoma.
JCI Insight 7: 2022 e154743
7
Chemical, Molecular, and Single-nucleus Analysis Reveal Chondroitin Sulfate Proteoglycan Aberrancy in Fibrolamellar Carcinoma.
Cancer Res Commun 2: 2022 663-678
2
DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma.
Cell Rep Med 5: 2024 101469
0
DNAJB1-PRKACA fusion protein-regulated LINC00473 promotes tumor growth and alters mitochondrial fitness in fibrolamellar carcinoma.
PLoS Genet 20: 2024 e1011216
1